Drugs / HEC110114
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05504876 | Nov → Dec 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04232514 | Jul → Aug 2020 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03903081 | Mar → Oct 2019 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04202952 | Jul → Aug 2020 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05395416 | Jun 2021 → Apr 2023 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC110114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05395416 ↗ |
| Route | Oral | “administered orally once daily” NCT03903081 ↗ |